{"id":836033,"date":"2025-04-10T09:13:39","date_gmt":"2025-04-10T13:13:39","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\/"},"modified":"2025-04-10T09:13:39","modified_gmt":"2025-04-10T13:13:39","slug":"nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\/","title":{"rendered":"Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">CAMBRIDGE, Mass.<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">April 10, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Nona Biosciences, a global biotechnology company providing integrated solutions from &#8220;Idea to IND&#8221; (I to I<sup>TM<\/sup>), ranging from target validation and antibody discovery through preclinical research, today announced a research collaboration with Atossa Therapeutics Inc. (Nasdaq: ATOS). The collaboration leverages Nona&#8217;s proprietary H2L2 Harbour Mice<sup>\u00ae<\/sup> platform to identify next-generation therapeutic candidates\u00a0for breast cancer.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2504641\/Nona_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2504641\/Nona_Logo.jpg\" title=\"(PRNewsfoto\/Nona Biosciences)\" alt=\"(PRNewsfoto\/Nona Biosciences)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>Nona Biosciences&#8217; proprietary Harbour Mice<sup>\u00ae<\/sup> platform employs transgenic mice to generate fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format, eliminating the need for additional engineering or humanization. Combined with the single B cell cloning technology, this platform offers a powerful approach to developing therapeutic antibodies and accelerating drug discovery and development. To date, Harbour Mice<sup>\u00ae<\/sup> platform has been applied in more than 250 drug discovery programs across multiple therapeutic areas and has been widely recognized by global partners.<\/p>\n<p>&#8220;We are pleased to collaborate with Atossa Therapeutics to discover next-generation antibody therapies for breast cancer,&#8221; said <span class=\"xn-person\">Jingsong Wang<\/span>, M.D., Ph.D., Chairman of Nona Biosciences. &#8220;This partnership highlights the value of our proprietary Harbour Mice<sup>\u00ae<\/sup> platform and reflects the industry&#8217;s growing demand for innovative antibody discovery solutions. With Nona&#8217;s industry-leading technology and expertise, we look forward to supporting Atossa&#8217;s exploration of antibody-based approaches within their oncology pipeline.&#8221;\u00a0<\/p>\n<p>\n        <b>About Nona Biosciences<\/b>\n      <\/p>\n<p>Nona Biosciences is a global biotechnology company committed to cutting-edge technology innovations and providing a total solution from &#8220;Idea to IND&#8221; (&#8220;I to I<sup>TM<\/sup>&#8220;),\u00a0ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice<sup>\u00ae<\/sup>\u00a0platforms and the experienced therapeutic antibody discovery team.<\/p>\n<p>Harbour Mice<sup>\u00ae<\/sup>\u00a0generates fully human monoclonal antibodies in classical\u00a0two light and two heavy chain (H2L2) format, and heavy chain-only (HCAb) format. Integrating Harbour Mice<sup>\u00ae<\/sup> and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit:\u00a0<a href=\"http:\/\/www.nonabio.com\/\" target=\"_blank\" rel=\"nofollow\">www.nonabio.com<\/a><b>.<\/b><\/p>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN62008&amp;sd=2025-04-10\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer-302425464.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer-302425464.html<\/a><\/p>\n<p>SOURCE  Nona Biosciences<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=CN62008&amp;Transmission_Id=202504100800PR_NEWS_USPR_____CN62008&amp;DateId=20250410\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire CAMBRIDGE, Mass. , April 10, 2025 \/PRNewswire\/ &#8212; Nona Biosciences, a global biotechnology company providing integrated solutions from &#8220;Idea to IND&#8221; (I to ITM), ranging from target validation and antibody discovery through preclinical research, today announced a research collaboration with Atossa Therapeutics Inc. (Nasdaq: ATOS). The collaboration leverages Nona&#8217;s proprietary H2L2 Harbour Mice\u00ae platform to identify next-generation therapeutic candidates\u00a0for breast cancer. Nona Biosciences&#8217; proprietary Harbour Mice\u00ae platform employs transgenic mice to generate fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format, eliminating the need for additional engineering or humanization. Combined with the single B cell cloning technology, this platform offers a powerful approach to developing &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-836033","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire CAMBRIDGE, Mass. , April 10, 2025 \/PRNewswire\/ &#8212; Nona Biosciences, a global biotechnology company providing integrated solutions from &#8220;Idea to IND&#8221; (I to ITM), ranging from target validation and antibody discovery through preclinical research, today announced a research collaboration with Atossa Therapeutics Inc. (Nasdaq: ATOS). The collaboration leverages Nona&#8217;s proprietary H2L2 Harbour Mice\u00ae platform to identify next-generation therapeutic candidates\u00a0for breast cancer. Nona Biosciences&#8217; proprietary Harbour Mice\u00ae platform employs transgenic mice to generate fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format, eliminating the need for additional engineering or humanization. Combined with the single B cell cloning technology, this platform offers a powerful approach to developing &hellip; Continue reading &quot;Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-10T13:13:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2504641\/Nona_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer\",\"datePublished\":\"2025-04-10T13:13:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\\\/\"},\"wordCount\":387,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2504641\\\/Nona_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\\\/\",\"name\":\"Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2504641\\\/Nona_Logo.jpg\",\"datePublished\":\"2025-04-10T13:13:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2504641\\\/Nona_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2504641\\\/Nona_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer - Market Newsdesk","og_description":"PR Newswire CAMBRIDGE, Mass. , April 10, 2025 \/PRNewswire\/ &#8212; Nona Biosciences, a global biotechnology company providing integrated solutions from &#8220;Idea to IND&#8221; (I to ITM), ranging from target validation and antibody discovery through preclinical research, today announced a research collaboration with Atossa Therapeutics Inc. (Nasdaq: ATOS). The collaboration leverages Nona&#8217;s proprietary H2L2 Harbour Mice\u00ae platform to identify next-generation therapeutic candidates\u00a0for breast cancer. Nona Biosciences&#8217; proprietary Harbour Mice\u00ae platform employs transgenic mice to generate fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format, eliminating the need for additional engineering or humanization. Combined with the single B cell cloning technology, this platform offers a powerful approach to developing &hellip; Continue reading \"Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-10T13:13:39+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2504641\/Nona_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer","datePublished":"2025-04-10T13:13:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\/"},"wordCount":387,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2504641\/Nona_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\/","name":"Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2504641\/Nona_Logo.jpg","datePublished":"2025-04-10T13:13:39+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2504641\/Nona_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2504641\/Nona_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/836033","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=836033"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/836033\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=836033"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=836033"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=836033"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}